tbuckley/cabot-search huggingface dataset:
REPLY: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB
Authors: Marc G. Ghany, Wendy C. King, Amanda S. Hinerman, Anna S.F. Lok, Mauricio Lisker-Melman, Raymond T. Chung, Norah Terrault, Harry L.A. Janssen, Mandana Khalili, William M. Lee, Daryl T.Y. Lau, Gavin A. Cloherty, Richard K. Sterling
Journal: Hepatology (2024)

Ghany, Marc G.; King, Wendy C.; Hinerman, Amanda S.; Lok, Anna S.F.; Lisker-Melman, Mauricio; Chung, Raymond T.; Terrault, Norah; Janssen, Harry L.A.; Khalili, Mandana; Lee, William M.; Lau, Daryl T.Y.; Cloherty, Gavin A.; Sterling, Richard K. Author Information
A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH): A Pilot Randomized Clinical Trial
Authors: Hermioni L. Amonoo, Elizabeth Daskalakis, Emma D. Wolfe, Michelle Guo, Christopher M. Celano, Brian C. Healy, Corey S. Cutler, Joseph H. Antin, William F. Pirl, Elyse R. Park, Heather S.L. Jim, Stephanie J. Lee, Thomas W. LeBlanc, Areej El-Jawahri, Jeff C. Huffman
Journal: Journal of the National Comprehensive Cancer Network (2024)

Background: Allogeneic hematopoietic stem cell transplantation (HSCT) survivors experience significant psychological distress and low levels of positive psychological well-being, which can undermine patient-reported outcomes (PROs), such as quality of life (QoL). Hence, we conducted a pilot randomized clinical trial to assess the feasibility and preliminary efficacy of a telephone-delivered positive psychology intervention (Positive Affect for the Transplantation of Hematopoietic stem cells intervention [PATH]) for improving well-being in HSCT survivors. Methods: HSCT survivors who were 100 days post-HSCT for hematologic malignancy at an academic institution were randomly assigned to either PATH or usual care. PATH, delivered by a behavioral health expert, entailed 9 weekly phone sessions on gratitude, personal strengths, and meaning. We defined feasibility a priori as &gt;60% of eligible participants enrolling in the study and &gt;75% of PATH participants completing ≥6 of 9 sessions. At baseline and 9 and 18 weeks, patients self-reported gratitude, positive affect, life satisfaction, optimism, anxiety, depression, posttraumatic stress disorder (PTSD), QoL, physical function, and fatigue. We used repeated measures regression models and estimates of effect size (Cohen’s d ) to explore the preliminary effects of PATH on outcomes. Results: We enrolled 68.6% (72/105) of eligible patients (mean age, 57 years; 50% female). Of those randomized to PATH, 91% completed all sessions and reported positive psychology exercises as easy to complete and subjectively useful. Compared with usual care, PATH participants reported greater improvements in gratitude (β = 1.38; d = 0.32), anxiety (β = −1.43; d = −0.40), and physical function (β = 2.15; d = 0.23) at 9 weeks and gratitude (β = 0.97; d = 0.22), positive affect (β = 2.02; d = 0.27), life satisfaction (β = 1.82; d = 0.24), optimism (β = 2.70; d = 0.49), anxiety (β = −1.62; d = −0.46), depression (β = −1.04; d = −0.33), PTSD (β = −2.50; d = −0.29), QoL (β = 7.70; d = 0.41), physical function (β = 5.21; d = 0.56), and fatigue (β = −2.54; d = −0.33) at 18 weeks. Conclusions: PATH is feasible, with promising signals for improving psychological well-being, QoL, physical function, and fatigue in HSCT survivors. Future multisite trials that investigate PATH’s efficacy are needed to establish its effects on PROs in this population.
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024
Authors: Jason Gotlib, Aaron T. Gerds, Peter Abdelmessieh, Haris Ali, Mariana Castells, Andrew Dunbar, Ruth Fein Revell, Tracy I. George, Steven Green, Krishna Gundabolu, Elizabeth Hexner, Tania Jain, Catriona Jamieson, Paul R. Kaesberg, Andrew T. Kuykendall, Yazan Madanat, Naveen Manchanda, Lucia Masarova, Jori May, Brandon McMahon, Sanjay R. Mohan, Kalyan V. Nadiminti, Stephen Oh, Jeanne Palmer, Ami Patel, Anand A. Patel, Nikolai Podoltsev, Lindsay Rein, Rachel Salit, Moshe Talpaz, Martha Wadleigh, Sarah Wall, Mary Anne Bergman, Cindy Hochstetler
Journal: Journal of the National Comprehensive Cancer Network (2024)

Mastocytosis is a heterogeneous group of disorders comprising cutaneous mastocytosis, systemic mastocytosis, and mast cell sarcoma. It is associated with a variety of symptoms related to the release of mast cell mediators and mast cell tissue infiltration. Referral to specialized centers with expertise in the management of mastocytosis and multidisciplinary collaboration with subspecialists (eg, allergists for the management of anaphylaxis and drug hypersensitivities, anesthesiologists for invasive procedures or surgery, high-risk obstetrician for pregnancy) is recommended. The NCCN Guidelines for Systemic Mastocytosis provide evidence- and consensus-based recommendations for the diagnosis and comprehensive care of patients with systemic mastocytosis. The multidisciplinary panel of experts convenes at least once a year to review requested changes to the guidelines from both internal and external entities as well as to discuss data on existing and new therapies. These NCCN Guidelines Insights focus on some of the recent updates to the guidelines.
Social, Disease, and Diagnostic Factors Associated with Diagnostic Delays in Dermatomyositis: A Retrospective Cohort Study
Authors: Lindsey J Wanberg, Nawang Singhe, Cody J Rasner, Joseph McGrath, Ziou Jiang, Karen Baker-James, Connor R Buechler, David R Pearson
Journal: British Journal of Dermatology (2024)

Adult patients with dermatomyositis from an academic tertiary referral centre experienced a range in durations of diagnostic delay, which were dependent on social, disease and diagnostic factors. About one-quarter of patients experienced a diagnostic delay ≥ 12 months, with a median of 3.5 months. Symptoms at initial presentation, zip code, skin biopsy results and treatment with systemic corticosteroids were associated with diagnostic delay duration.
Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors
Authors: Oscar Hou In Chou, Jing Ning, Raymond Ngai Chiu Chan, Cheuk To Chung, Helen Huang, Kenrick Ng, Edward Christopher Dee, Sharen Lee, Apichat Kaewdech, Ariel K Man Chow, Nancy Kwan Man, Tong Liu, Fengshi Jing, Bernard Man Yung Cheung, Gary Tse, Jiandong Zhou
Journal: Journal of the National Comprehensive Cancer Network (2024)

Background: Type 2 diabetes mellitus (T2DM) may be a risk factor for development of hepatocellular carcinoma (HCC). The association between risk of developing HCC and treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus dipeptidyl peptidase-4 inhibitors (DPP4i) is currently unknown. This study aimed to compare the risk of new-onset HCC in patients treated with SGLT2i versus DPP4i. Methods: This was a retrospective cohort study of patients with T2DM in Hong Kong receiving either SGLT2i or DPP4i between January 1, 2015, and December 31, 2020. Patients with concurrent DPP4i and SGLT2i use were excluded. Propensity score matching (1:1 ratio) was performed by using the nearest neighbor search. Multivariable Cox regression was applied to identify significant predictors. Results: A total of 62,699 patients were included (SGLT2i, n=22,154; DPP4i, n=40,545). After matching (n=44,308), 166 patients (0.37%) developed HCC: 36 in the SGLT2i group and 130 in the DPP4i group over 240,269 person-years. Overall, SGLT2i use was associated with lower risks of HCC (hazard ratio [HR], 0.42; 95% CI, 0.28–0.79) compared with DPP4i after adjustments. The association between SGLT2i and HCC development remained significant in patients with cirrhosis or advanced fibrosis (HR, 0.12; 95% CI, 0.04–0.41), hepatitis B virus (HBV) infection (HR, 0.32; 95% CI, 0.17–0.59), or hepatitis C virus (HCV) infection (HR, 0.41; 95% CI, 0.22–0.80). The results were consistent in different risk models, propensity score approaches, and sensitivity analyses. Conclusions: SGLT2i use was associated with a lower risk of HCC compared with DPP4i use after adjustments, and in the context of cirrhosis, advanced fibrosis, HBV infection, and HCV infection.
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Authors: Al B. Benson, Alan P. Venook, Mohamed Adam, George Chang, Yi-Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, Paul Haste, J. Randolph Hecht, Sarah Hoffe, Steven Hunt, Hisham Hussan, Kimberly L. Johung, Nora Joseph, Natalie Kirilcuk, Smitha Krishnamurthi, Midhun Malla, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, Benjamin Shogan, John M. Skibber, Constantinos T. Sofocleous, Anna Tavakkoli, Christopher G. Willett, Christina Wu, Lisa A. Gurski, Jenna Snedeker, Frankie Jones
Journal: Journal of the National Comprehensive Cancer Network (2024)

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. Management of disseminated metastatic CRC involves various active drugs, either in combination or as single agents. The choice of therapy is based on consideration of the goals of therapy, the type and timing of prior therapy, the mutational profile of the tumor, and the differing toxicity profiles of the constituent drugs. This manuscript summarizes the data supporting the systemic therapy options recommended for metastatic CRC in the NCCN Guidelines for Colon Cancer.
NCCN News
Authors: Cecile Ferrando
Journal: Journal of the National Comprehensive Cancer Network (2024)

On May 6, 2024, NCCN hosted an oncology policy summit focused on how sexual and reproductive health can impact people with cancer before, during, and after treatment.Speakers covered a wide range of topics within the context of gender and sex, intimacy, fertility and reproductive health, treatment side effects, and the impact of a changing policy landscape in the wake of new laws and judicial decisions.The summit began with an introduction from NCCN's Chief Executive Officer, Crystal S. Denlinger, MD, who previously served for many years as Chair of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Panel for Survivorship.These evidence-based expert-consensus recommendations feature best practices for addressing sexual health, fertility, hormone-related symptoms, and many other late and long-term effects from cancer.The clinician-facing NCCN Guidelines for Survivorship, as well as a patient-and caregiver-friendly format, are all available for free at NCCN.org or via the Virtual Library of NCCN Guidelines App.Dr. Denlinger remarked, "We can't overlook the importance of quality of life for people being treated for cancer and those in remission.High-quality cancer care means addressing any barriers preventing patients from living their best possible life.When it comes to sexual and reproductive health, lack of discussion can be a significant limitation.That is why we have brought together a diverse group of experts to take part in these delicate but important conversations.""Research strongly suggests that oncologists and other cancer clinicians receive little training on how to discuss sexual health and related concerns with their patients, to the detriment of their patients' care and health outcomes," added Jennifer Barsky Reese, PhD, FSBM, Associate Professor, Cancer Prevention and Control Program, Fox Chase Cancer Center."It is so important that education about sexual and reproductive health be included into the training of cancer clinicians if these critical health issues are to be addressed in patients' comprehensive cancer care.""No one should feel like they have to suffer just because they've been diagnosed with cancer," agreed panelist Mindy Goldman, MD, UCSF Helen Diller Family Comprehensive Cancer Center, and member of the NCCN Guidelines Panel for Survivorship."Early menopause is a seldom-discussed but frequent side effect from cancer treatment.We have options to address the symptoms, but patients are often afraid to bring them up or don't know who to talk to about them, and clinicians may also consider it to be a taboo topic.Patients seeking answers will often find themselves confused or relying on unvetted online material.We hope that by including recommendations on treatment for sexual function issues in the NCCN Guidelines, we can help people have the information they need to facilitate these necessary conversations with their care providers."
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases
Authors: Shouzhi Yang, Jing Fu, Wenhao Qin, Ruimin Wang, Mingye Gu, Yida Huang, Wanshan Liu, Haiyang Su, Xiaoyu Xu, Wei Chen, Ayizekeranmu Yiming, Bing Hu, Lin Huang, Kun Qian, Hongyang Wang
Journal: Hepatology (2024)

Background and Aims: Biliary tract cancers are aggressive gastrointestinal malignancies characterized by a dismal 5-year overall survival rate &lt;20%. Current diagnostic modalities suffer from limitations regarding sensitivity and specificity. This study aimed to develop a bile metabolite–based platform for precise discrimination between malignant and benign biliary diseases. Approach and Results: Samples were collected from 336 patients with biliary tract cancer or benign biliary diseases across 3 independent cohorts. Untargeted metabolic fingerprinting was performed on 300 bile samples using novel nanoparticle-enhanced laser desorption/ionization mass spectrometry. Subsequently, a diagnostic assay was developed based on the exploratory cohort using a selected bile metabolic biomarker panel, with performance evaluated in the validation cohort. Further external validation of disease-specific metabolites from bile samples was conducted in a prospective cohort (n = 36) using quantitative analysis. As a result, we established a novel bile-based assay, BileMet, for the rapid and precise detection of malignancies in the biliary tract system with an AUC of 0.891. We identified 6-metabolite biomarker candidates and discovered the critical role of the chenodeoxycholic acid glycine conjugate as a protective metabolite associated with biliary tract cancer. Conclusions: Our findings confirmed the improved diagnostic capabilities of BileMet assay in a clinical setting. If applied, the BileMet assay enables intraoperative testing and fast medical decision-making for cases with suspected malignancy where brush cytology detection fails to support malignancy, ultimately reducing the economic burden by over 90%.
Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Authors: Yinyin Shu, Xiaoni Jin, Mintao Ji, Zhisen Zhang, Xiuxiu Wang, Haisheng Liang, Shuangshuang Lu, Shuai Dong, Yiping Lin, Yuhan Guo, Qiuyu Zhuang, Yuhong Wang, Zhe Lei, Lingchuan Guo, Xuanyu Meng, Guangming Zhou, Wensheng Zhang, Lei Chang
Journal: Cancer Research (2024)

Abstract Yes-associated protein (YAP) is a central player in cancer development, with functions extending beyond its recognized role in cell growth regulation. Recent work has identified a link between YAP/transcriptional coactivator with PDZ-binding motif (TAZ) and the DNA damage response. Here, we investigated the mechanistic underpinnings of the cross-talk between DNA damage repair and YAP activity. Ku70, a key component of the nonhomologous end joining pathway to repair DNA damage, engaged in a dynamic competition with TEAD4 for binding to YAP, limiting the transcriptional activity of YAP. Depletion of Ku70 enhanced interaction between YAP and TEAD4 and boosted YAP transcriptional capacity. Consequently, Ku70 loss enhanced tumorigenesis in colon cancer and hepatocellular carcinoma (HCC) in vivo. YAP impeded DNA damage repair and elevated genome instability by inducing PARP1 degradation through the SMURF2-mediated ubiquitin-proteasome pathway. Analysis of samples from patients with HCC substantiated the link between Ku70 expression, YAP activity, PARP1 levels, and genome instability. In conclusion, this research provides insight into the mechanistic interactions between YAP and key regulators of DNA damage repair, highlighting the role of a Ku70-YAP-PARP1 axis in preserving genome stability. Significance: Increased yes-associated protein transcriptional activity stimulated by loss of Ku70 induces PARP1 degradation by upregulating SMURF2 to inhibit DNA damage, driving genome instability and tumorigenesis.
Erratum. Atypical Diabetes: What Have We Learned and What Does the Future Hold? Diabetes Care 2024;47:770–781
Authors: Stephen I. Stone, Ashok Balasubramanyam, Jennifer E. Posey
Journal: Diabetes Care (2024)

On p. 777 of the article cited above, it was incorrectly stated that patients with pancreatic diabetes may have elevated fecal elastase. The correct text is as follows:
In vivo CAR T-cell generation in non-human primates using lentiviral vectors displaying a multi-domain fusion ligand
Authors: Christopher James Nicolai, Maura Parker, Jim Qin, Weiliang Tang, Justin Theophilus Ulrich-Lewis, Rebecca Gottschalk, Sara Cooper, Susana A Hernandez Lopez, Don Parrilla, Richard Mangio, Nolan Ericson, Alissa Brandes, Saluwa Umuhoza, Kathryn Michels, Mollie McDonnell, Lisa Park, Seungjin Shin, Wai-Hang Leung, Andrew Scharenberg, Hans-Peter Kiem, Ryan Peter Larson, Laurie Beitz, Byoung Ryu
Journal: Blood (2024)
Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in Relapsed/Refractory CLL: Phase 1b BRUIN Trial
Authors: Lindsey Elizabeth Roeker, Jennifer A. Woyach, Chan Yoon Y Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda, Manish R. Patel, Nicole Lamanna, Donald E Tsai, Binoj Chandrasekharan Nair, Chunxiao Wang, Xiang Zhao, Dan Liu, David Radtke, Sonya Chapman, Narasimha Marella, Samuel C McNeely, Jennifer R. Brown
Journal: Blood (2024)
Neuroblastoma Predisposition and Surveillance—An Update from the 2023 AACR Childhood Cancer Predisposition Workshop
Authors: Junne Kamihara, Lisa R. Diller, William D. Foulkes, Orli Michaeli, Yoshiko Nakano, Kristian W. Pajtler, Melissa Perrino, Sarah R. Scollon, Douglas R. Stewart, Stephan Voss, Rosanna Weksberg, Jordan R. Hansford, Garrett M. Brodeur
Journal: Clinical Cancer Research (2024)

Genetic predisposition to neuroblastoma (NB) is relatively rare. Only 1% to 2% of patients have a family history of NB, 3% to 4% of cases present with bilateral or multifocal primary tumors, and occasional patients have syndromes that are associated with increased NB risk. Previously, a germline pathogenic variant (GPV) in PHOX2B was associated with Hirschsprung disease and congenital central hypoventilation syndrome. Recently, certain GPVs were shown to be responsible for congenital central hypoventilation syndrome and NB predisposition. Also, several groups determined that activating GPVs in ALK accounted for a substantial number of familial NB. Finally, there are additional genes and cancer predisposition syndromes in which NB occurs with greater frequency or that have been associated with NB based on genome-wide association studies. We review the evidence for all these genes and whether there is sufficient evidence to warrant surveillance. We review recommended surveillance for hereditary patients with NB, including minor updates to surveillance recommendations that were published previously in 2017.
Plasma Biomarkers of Brain Injury and Their Association With Brain MRI and Cognition in Type 1 Diabetes
Authors: Amy B. Karger, Ilya M. Nasrallah, Barbara H. Braffett, José A. Luchsinger, Christopher M. Ryan, Ionut Bebu, Valerie Arends, Mohamad Habes, Rose A. Gubitosi-Klug, Naomi Chaytor, Geert J. Biessels, Alan M. Jacobson
Journal: Diabetes Care (2024)

To evaluate associations between plasma biomarkers of brain injury and MRI and cognitive measures in participants with type 1 diabetes (T1D) from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.
Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial
Authors: Jiwei Huang, Yueming Wang, Fan Xu, Zaoyu Wang, Guangyu Wu, Wen Kong, NG Cheoklong, Thibault Tricard, Xiaorong Wu, Wei Zhai, Wei Zhang, Jiyang Zhang, Ding Zhang, Shuyin Chen, Yuqing Lian, Yonghui Chen, Jin Zhang, Yiran Huang, Wei Xue
Journal: Journal for ImmunoTherapy of Cancer (2024)

A combination of axitinib and immune checkpoint inhibitors (ICIs) demonstrated promising efficacy in the treatment of advanced renal cell carcinoma (RCC). This study aims to prospectively evaluate the safety, efficacy, and biomarkers of neoadjuvant toripalimab plus axitinib in non-metastatic clear cell RCC. This is a single-institution, single-arm phase II clinical trial. Patients with non-metastatic biopsy-proven clear cell RCC (T2-T3N0-1M0) are enrolled. Patients will receive axitinib 5 mg twice daily combined with toripalimab 240 mg every 3 weeks (three cycles) for up to 12 weeks. Patients then will receive partial (PN) or radical nephrectomy (RN) after neoadjuvant therapy. The primary endpoint is objective response rate (ORR). Secondary endpoints include disease-free survival, safety, and perioperative complication rate. Predictive biomarkers are involved in exploratory analysis. A total of 20 patients were enrolled in the study, with 19 of them undergoing surgery. One patient declined surgery. The primary endpoint ORR was 45%. The posterior distribution of πORR had a mean of 0.44 (95% credible intervals: 0.24-0.64), meeting the predefined primary endpoint with an ORR of 32%. Tumor shrinkage was observed in 95% of patients prior to nephrectomy. Furthermore, four patients achieved a pathological complete response. Grade ≥3 adverse events occurred in 25% of patients, including hypertension, hyperglycemia, glutamic pyruvic transaminase/glutamic oxaloacetic transaminase (ALT/AST) increase, and proteinuria. Postoperatively, one grade 4a and eight grade 1-2 complications were noted. In comparison to patients with stable disease, responders exhibited significant differences in immune factors such as Arginase 1(ARG1), Melanoma antigen (MAGEs), Dendritic Cell (DC), TNF Superfamily Member 13 (TNFSF13), Apelin Receptor (APLNR), and C-C Motif Chemokine Ligand 3 Like 1 (CCL3-L1). The limitation of this trial was the small sample size. Neoadjuvant toripalimab combined with axitinib shows encouraging activity and acceptable toxicity in locally advanced clear cell RCC and warrants further study. clinicaltrials.gov, NCT04118855.